Some price data may be temporarily unavailable.
The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-Oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.